Nutlin-3, also known by its CAS number 890090-75-2, is a small molecule inhibitor of the MDM2-p53 interaction. It has gained attention in recent years due to its potential therapeutic benefits in treating various types of cancer.
Introduce this product: Nutlin-3 is a small molecule that acts as an antagonist of the MDM2 protein, which binds to and inhibits the tumor suppressor p53. By blocking this interaction, Nutlin-3 can activate p53 and induce apoptosis in cancer cells.
Chemical name: The chemical name of Nutlin-3 is (4S)-4-(4-Chlorophenyl)-1-(4-nitrophenyl)-2,3,4,5-tetrahydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid ethyl ester.
Molecular formula: The molecular formula of Nutlin-3 is C30H30ClN5O5.
Formula weight: The formula weight of Nutlin-3 is 581.04 g/mol.
CAS No: The CAS number of Nutlin-3 is 890090-75-2.
Top ten keywords from Google and Synonyms:
Synonyms for Nutlin-3 include RG7112 and 890090-75-2.
Health benefits of this product: Nutlin-3 has the potential to provide numerous health benefits in the treatment of various types of cancer. As a small molecule inhibitor of the MDM2-p53 interaction, it can activate p53 and induce apoptosis in cancer cells. This can help slow or stop the growth of tumors and improve survival rates.
Potential effects: The potential effects of Nutlin-3 are vast and varied. Its ability to activate p53 and induce apoptosis in cancer cells makes it a promising candidate for the treatment of various types of cancer. Additionally, Nutlin-3 has shown promise in combination with chemotherapy and other molecular targeted therapies in improving treatment outcomes.
Product mechanism: Nutlin-3 works by binding to the hydrophobic pocket of MDM2, a protein that binds to and inhibits p53. By blocking this interaction, Nutlin-3 can activate p53 and induce apoptosis in cancer cells. This can help slow or stop the growth of tumors and improve survival rates.
Safety: While Nutlin-3 has shown significant promise in preclinical studies, its safety profile in humans remains unknown. As with any new medication, it will need to undergo extensive clinical trials to confirm its efficacy and safety before it can be approved for use. It is essential to consult a healthcare professional before starting any new medication or treatment regimen.
Side effects: As a new medication, the potential side effects of Nutlin-3 are not yet fully understood. However, based on preclinical studies, it appears to have a favorable side effect profile compared to traditional chemotherapy. Nevertheless, some potential side effects include gastrointestinal distress, headache, fatigue, and muscle weakness.
Dosing information: As Nutlin-3 is still in the preclinical phase of development, dosing information is not yet available. However, it is likely that dosages will vary depending on the severity of the cancer being treated, the patient's age, weight, and other factors. It is crucial to follow the advice of a healthcare professional when taking any medication.
Conclusion: In conclusion, Nutlin-3 shows significant potential in treating various types of cancer. As a small molecule inhibitor of the MDM2-p53 interaction, it provides greater specificity and fewer side effects than non-selective chemotherapy treatments. However, more research is needed to confirm its efficacy and safety before it can be approved for use. It is essential to consult a healthcare professional before starting any new medication or treatment regimen
